First quarter 2022 results
First quarter 2022 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
Featuring
Paul Hudson
Chief Executive Officer
Jean-Baptiste de Chatillon
Chief Financial Officer
Bill Sibold
Specialty Care
Olivier Charmeil
General Medicines
John Reed
R&D
Thomas Triomphe
Vaccines
Julie Van Ongevalle
Consumer Healthcare
Roy Papatheodorou
General Counsel
Highlights
Paul Hudson comments on first quarter 2022 results
Highlights of the first quarter 2022 results
We’re off to a good start in 2022 thanks to a strong commitment to our strategy. We’re proud of the progress made in Immunology, with a broad pipeline of 13 potential new treatments in development.
Paul Hudson
Chief Executive Officer, Sanofi